DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1494)

Neuropathic Pain | Unmet Need | Detailed Expanded Analysis Painful Diabetic Neuropathy

Neuropathic Pain | Unmet Need | Detailed Expanded Analysis Painful Diabetic Neuropathy

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Painful diabetic neuropathy ( PDN ), a subset of diabetic neuropathy; affects approximately seven million people in the United States and major European markets. The primary goal of treating PDN is to reduce the severity and prevent worsening of the pain while improving the patient’s QOL . The most frequently prescribed drugs for treating PDN are Lyrica (Pfizer), gabapentin (Pfizer’s Neurontin, generics), duloxetine (Eli Lilly/Boehringer Ingelheim’s Cymbalta/Xeristar, generics), Nucynta ER /Palexia SR/Yantil (Janssen/Depomed/Grünenthal), and Qutenza (Acorda/Grünenthal). The goal of treatment with all of these agents is to provide adequate analgesia to patients, each of whom may respond differently to these therapies. Despite the availability of these agents and an armamentarium of other drugs in the United States and Europe to treat PDN , opportunity remains in the PDN market for new agents that can address existing unmet needs, such as the need for products with more efficacious and safer profiles.
This Unmet Need content provides quantitative insight into and European neurologists’ perceptions of key treatment drivers and goals in the treatment of PDN and the current level of unmet need in this indication. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.
Questions Answered:

What are the treatment drivers and goals for PDN ?
What attributes are key influencers, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for PDN ?
What are the prevailing areas of unmet need and opportunity in PDN ?
What trade-offs across different clinical attributes and price are acceptable to and European neurologists for a hypothetical new PDN drug?

Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 and 32 European neurologists fielded in December 2016
Key companies:  AbbVie, Acorda Therapeutics, Astellas Pharma, Boehringer Ingelheim, Depomed, Eli Lilly, Grünenthal, Janssen, and Pfizer
Key drugs: Amitriptyline, duloxetine, gabapentin, Lyrica, Qutenza, tapentadol ER , and Vicodin

  • Pub Date: August 2017
  • Author(s): Audreza Das, P.G. Dip

Request report

Related reports:
You may also be interested in: